Drug Trial Radar · NCT05849272
Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression
Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 12, 2023
Primary completion
May 8, 2024
Study completion May 8, 2024
Sponsor
- Lead sponsor
- Shanghai Mental Health CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of somatic symptoms in depression, to provide evidence-based basis for clinical rational drug use.
Conditions
- Somatic Symptom
Interventions
toludesvenlafaxine hydrochloride sustained-release tabletsDrug
orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Health Questionnaire-15 (PHQ-15)Time frame: 8 Weeks
- The Chinese version of the Somatization Symptom Scale (SSS-CN)Time frame: 8 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.